Myelofibrosis - Epidemiology Forecast - 2034

Myelofibrosis - Epidemiology Forecast - 2034

Key Highlights

Myelofibrosis consists of two entities: primary myelofibrosis and post–polycythemia vera (PPV) and post–essential thrombocythemia (PET) myelofibrosis, also known as secondary myelofibrosis.

Mutations in the JAK2, MPL, CALR, and TET2 genes are associated with most cases of primary myelofibrosis. The JAK2 and MPL genes provide instructions for making proteins that promote the growth and division (proliferation) of blood cells.

Approximately 90% of patients with myelofibrosis have a mutation of the JAK2, MPL, or CALR gene. The approximate frequencies of these mutations are JAK2 mutation: 60%, CALR mutation: 20–35%, and MPL mutation: 5–8%. About 10% of myelofibrosis patients do not have a JAK2, MPL, or CALR gene mutation. In these cases, the disease is referred to as “triple-negative” myelofibrosis and is associated with a worse prognosis (outcome).

Prevalence rates of myelofibrosis have increased than previously reported, which may be explained by improved diagnostics, increased offerings for preventive checkups, and the classification change of prefibrotic myelofibrosis by the WHO in 2016.

The total prevalent cases of myelofibrosis in the United States were nearly 19,300 in 2023. These cases are expected to rise during the forecast period (2024-2034).

DelveInsight’s ‘Myelofibrosis - Epidemiology Forecast—2034’ report delivers an in-depth understanding of the myelofibrosis, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Myelofibrosis: Disease Understanding

Myelofibrosis Overview

Myelofibrosis is a rare type of blood cancer characterized by the buildup of scar tissue, called “fibrosis,” in the bone marrow. The bone marrow cannot make enough healthy blood cells due to increased scar tissue. It is one of the related groups of blood cancers known as “myeloproliferative neoplasms (MPNs)” in which blood cells produced by bone marrow cells develop and function abnormally. When myelofibrosis develops on its own (and not as the result of another bone marrow disease), it is called primary myelofibrosis. In other cases, another type of MPN, such as polycythemia vera (PV) or essential thrombocythemia (ET), can transform into myelofibrosis. In these cases, it is known as secondary myelofibrosis, which may also be referred to as post-PV myelofibrosis or post-ET myelofibrosis.

Myelofibrosis usually develops slowly, and it often does not cause early symptoms and may be found during a routine blood test. When fibrosis develops in the bone marrow, the bone marrow is unable to produce enough normal blood cells. The lack of blood cells causes many signs and symptoms of myelofibrosis. Several specific gene mutations have been identified in people with myelofibrosis. The most common is the Janus kinase 2 (JAK2) gene mutation, and other less common mutations include CALR and MPL. Some people with myelofibrosis do not have any identifiable gene mutations.

Prominent clinical features in myelofibrosis include anemia, hepatosplenomegaly, and constitutional symptoms including fatigue, night sweats, low-grade fever, and progressive cachexia with loss of muscle mass, bone pain, splenic infarct, pruritus, non hepatosplenic EMH, thrombosis, and bleeding.

Myelofibrosis Diagnosis

Myelofibrosis can be diagnosed by using a series of tests such as blood tests, bone marrow tests, molecular testing, and mutation-enhanced morphologic diagnosis. To confirm the diagnosis, the doctor tests the bone marrow. Bone marrow testing involves two steps usually performed at the same time in a doctor’s office or a hospital: a bone marrow aspiration removes a liquid marrow sample, and a bone marrow biopsy removes a small amount of bone filled with marrow. Molecular tests are used for diagnosis to look for abnormal changes in the genes, chromosomes, proteins, or other molecules within the patient’s cancer cells.

Further details in the report...

Myelofibrosis Epidemiology

The myelofibrosis epidemiology division provides insights into the historical and current myelofibrosis patient pool and forecasted trends for seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. The disease epidemiology covered in the report provides historical as well as forecasted myelofibrosis epidemiology segmented by total prevalent cases, type-specific cases, myelofibrosis cases based on risk stratification, age-specific cases, and myelofibrosis cases based on molecular alterations in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom and Japan from 2020 to 2034.

The total prevalent cases of myelofibrosis in the 7MM were nearly 56,700 in 2023 and is projected to increase during the study period (2020–2034).

Among the EU4 and the UK, Germany accounted for the highest number of myelofibrosis diagnosed prevalent cases, followed by the Spain, whereas the UK accounted for the lowest number of cases in 2023.

Based on risk, myelofibrosis cases are stratified as low risk, intermediate-1 risk, intermediate-2, and high risk. The high-risk accounted for the highest number of patients in 2023 in the US.

Myelofibrosis can be further categorized into primary myelofibrosis and secondary myelofibrosis. In 2023, primary myelofibrosis accounted for 75% of all cases in the US.

In the US, based on age, myelofibrosis cases are stratified in the age group =49 years, 40-69 years, and =70 years. =70 years of age group accounted for the highest number of patients i.e. nearly 12,200 in 2023 in the US.

In the US, the cases of JAK2 mutations account for approximately 60% in 2023.

KOL-Views

To keep up with current epidemiology trends, we take KOLs and SMEs’ opinions working in the myelofibrosis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate Myelofibrosis epidemiology trends.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of myelofibrosis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.

Comprehensive insight into the epidemiology segments and forecasts and disease progression has been provided.

The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journeys in the 7MM.

A detailed review of current challenges in establishing the diagnosis.

Myelofibrosis Report Insights

Patient Population

Country-wise Epidemiology Distribution

Age-wise cases of myelofibrosis

Myelofibrosis Report Key Strengths

Eleven Years Forecast

The 7MM Coverage

Myelofibrosis Epidemiology Segmentation

Myelofibrosis Report Assessment

Current Diagnostic Practices

Epidemiology Insights

What are the disease risks, burdens, and unmet needs of myelofibrosis? What will be the growth opportunities across the 7MM concerning the patient population with myelofibrosis?

What is the historical and forecasted myelofibrosis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the age-specific myelofibrosis prevalence cases in varying geographies over the coming years.

To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.